Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bankrolling BetaKine

Bankrolling BetaKine

Celtrix Pharmaceuticals Inc. and Genzyme Corp. agreed to develop BetaKine transforming growth factor-beta-2 (TGF-beta-2) for tissue repair, treatment of multiple sclerosis and other systemic applications.

Not counting milestones, GENZ will invest $70-80 million in the project, of which $30-40 million will go to CTRX.

Read the full 459 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE